1. Home
  2. INDP vs NCRA Comparison

INDP vs NCRA Comparison

Compare INDP & NCRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Indaptus Therapeutics Inc.

INDP

Indaptus Therapeutics Inc.

HOLD

Current Price

$2.41

Market Cap

5.2M

Sector

Health Care

ML Signal

HOLD

Logo Nocera Inc.

NCRA

Nocera Inc.

HOLD

Current Price

$0.21

Market Cap

5.6M

ML Signal

HOLD

Company Overview

Basic Information
Metric
INDP
NCRA
Founded
2000
2002
Country
United States
Taiwan
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Farming/Seeds/Milling
Sector
Health Care
Consumer Staples
Exchange
Nasdaq
Nasdaq
Market Cap
5.2M
5.6M
IPO Year
2021
2022

Fundamental Metrics

Financial Performance
Metric
INDP
NCRA
Price
$2.41
$0.21
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
67.1K
550.9K
Earning Date
05-11-2026
04-15-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$13,627,944.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.27
$0.17
52 Week High
$13.24
$2.40

Technical Indicators

Market Signals
Indicator
INDP
NCRA
Relative Strength Index (RSI) 45.22 43.28
Support Level $2.36 $0.18
Resistance Level $3.11 $0.24
Average True Range (ATR) 0.41 0.02
MACD -0.07 0.01
Stochastic Oscillator 25.71 53.90

Price Performance

Historical Comparison
INDP
NCRA

About INDP Indaptus Therapeutics Inc.

Indaptus Therapeutics Inc is a clinical biotechnology company that has developed a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. Its approach is based on the hypothesis that efficient activation of both innate and adaptive immune cells and associated anti-tumor and anti-viral immune responses will require a multi-targeted package of immune system activating signals that can be administered safely intravenously. Its patented technology is composed of single strains of attenuated and killed, non-pathogenic, Gram-negative bacteria, designed to have reduced i.v. toxicity, but largely uncompromised ability to prime or activate many of the cellular components of innate and adaptive immunity. Its candidate, Decoy20 is for patients with solid tumors.

About NCRA Nocera Inc.

Nocera Inc is engaged in the manufacturing of aquaculture equipment, construction of aquaculture facilities, managing and operating aquaculture facilities, and consulting for third-party operators of aquaculture facilities. Its primary business operations consist of the design, development, and production of RASs large-scale fish tank systems, for fish farms along with consulting, technology transfer, and aquaculture project management services to new and existing aquaculture management business services.

Share on Social Networks: